20. Blood pressure reducing and antioxidant effects of Nano Rutin on Wistar rats with hypertension model caused by N(G)-nitro-L-arginine-methyl ester (L-NAME)

Nguyen Hong Hanh, Nguyen Hoang Ngan, Nguyen Thi Thanh Tu

Main Article Content

Abstract

This study aimed to evaluate the blood pressure reducing and antioxidant effects of Nano Rutin on Wistar rats with hypertension model caused by N(G)-nitro-L-arginine-methyl ester (L-NAME). The Wistar rats were randomly allocated into 5 groups with 12 animals in each group. Group 1 was non- hypertensive rats. With the remaining 4 groups, the rats were induced to become hpertensive by orally administrating L-NAME (0.5% w/v diluted in distilled water), at 50 mg/kg b.w./day; group 2 was administered with distilled water; group 3 was administered with Losartan at 25mg/kg b.w./day; group 4 was administered with Nano Rutin at 280 mg/kg b.w./day and group 5 was administered with Nano Rutin at 560 mg/kg b.w./day. The duration to take the reagents was 4 weeks. The systolic, the diastolic pressure and the heart rate were assessed at baseline, after 1 week, 2 weeks, 3 weeks and 4 weeks of treatment. The serum levels of nitric oxide (NO) and compounds determining the anti-oxidant capacity such as Superoxide dismutase (SOD), glutathione (GSH), malondylaldehyde (MDA) were assessed at baseline and after 4 weeks of treatment. The results showed that Nano Rutin at the doses of 280 mg/kg b.w. and 560 mg/kg b.w. was effective in preventing L-NAME-induced hypertension in Wistar rats and did not alter the rats’ heart rates. In addition, Nano Rutin increased the serum NO level and the antioxidant capacity in rats administered L-NAME (increased SOD, GSH and decreased MDA).

Article Details

References

1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. doi:10.1038/s41581-019-0244-2
2. Zhou Y, Jia L, Lu B, et al. Updated hypertension prevalence, awareness, and control rates based on the 2017ACC/AHA high blood pressure guideline. J Clin Hypertens (Greenwich). 2019;21(6):758-765. doi:10.1111/jch.13564
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1
4. Biswas T, Tran N, Thi My Hanh H, et al. Type 2 diabetes and hypertension in Vietnam: a systematic review and meta-analysis of studies between 2000 and 2020. BMJ Open. 2022;12(8):e052725. doi:10.1136/bmjopen-2021-052725
5. Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75(2):285-292. doi:10.116 1/HYPERTENSIONAHA.119.14240
6. Whelton PK, Carey RM, Mancia G, et al. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations. Circulation. 2022;146(11):868-877. doi:10.1161/CIRCULATIONAHA.121.054602
7. Joshi VD, Dahake AP, Suthar AP. Adverse Effects Associated with the Use of Antihypertensive Drugs: An Overview. International Journal of PharmTech Research. 2010;2(1).
8. Sharma S, Ali A, Ali J, et al. Rutin: therapeutic potential and recent advances in drug delivery. Expert Opinion on Investigational Drugs. 2013;22(8):1063-1079. doi:10.1517/13543784.2013.805744
9. Gullón B, Lú-Chau TA, Moreira MT, et al. Rutin: A review on extraction, identification and purification methods, biological activities and approaches to enhance its bioavailability. Trends in Food Science & Technology. 2017;67:220-235. doi:10.1016/j.tifs.2017.07.008
10. Bilanda DC, Dzeufiet PDD, Kouakep L, et al. Bidens pilosa Ethylene acetate extract can protect against L-NAME-induced hypertension on rats. BMC Complement Altern Med. 2017;17(1):479. doi:10.1186/s12906-017-1972-0
11. Meaney E, Alva F, Moguel R, et al. Formula and nomogram for the sphygmomanometric calculation of the mean arterial pressure. Heart (British Cardiac Society). 2000;84:64.
12. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med. 2007;43(5):645-657. doi:10.1016/j.freeradbiomed.2007.04.026
13. Negahdari R, Bohlouli S, Sharifi S, et al. Therapeutic benefits of rutin and its nanoformulations. Phytotherapy Research. 2021;35(4):1719-1738. doi:10.1002/ptr.6904
14. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2021;8:798958. doi:10.3389/fme d.2021.798958
15. Tousoulis D, Kampoli AM, Tentolouris C, et al. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4-18. doi:10.2174/157016112798829760
16. Scrogin KE, Hatton DC, Chi Y, et al. Chronic nitric oxide inhibition with L-NAME: effects on autonomic control of the cardiovascular system. Am J Physiol. 1998;274(2):R367-374. doi:10.1152/ajpregu.1998.274.2.R367
17. Greish SM, Abdel-Hady Z, Mohammed SS, et al. Protective potential of curcumin in L-NAME-induced hypertensive rat model: AT1R, mitochondrial DNA synergy. Int J Physiol Pathophysiol Pharmacol. 2020;12(5):134-146.
18. Sharma S, Ali A, Ali J, et al. Rutin : therapeutic potential and recent advances in drug delivery. Expert Opin Investig Drugs. 2013;22(8):1063-1079. doi:10.1517/13543784.2013.805744
19. Kaur S, Muthuraman A. Therapeutic evaluation of rutin in two-kidney one-clip model of renovascular hypertension in rat. Life Sciences. 2016;150:89-94. doi:10.1016/j.lfs.2016.02.080
20. Olaleye M, Crown O, Akinmoladun A, et al. Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride-induced hypertensive rats. Hum Exp Toxicol. 2014;33(6):602-608. doi:10.1177/096 0327113504790
21. Fortepiani LA, Ortíz MC, Atucha NM, et al. Nebivolol ameliorates nitric oxide deficient hypertension. The Scientific World Journal. 2002;2: 1676-1684. doi:10.1100/tsw.2002.814
22. Khedara A, Kawai Y, Kayashita J, et al. Feeding rats the nitric oxide synthase inhibitor, L-N(omega)nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr. 1996;126(10):2563-2567. doi:10.1093/jn/126.10.2563
23. Bilanda DC, Dzeufiet PDD, Kouakep L, et al. Bidens pilosa Ethylene acetate extract can protect against L-NAME-induced hypertension on rats. BMC Complement Altern Med. 2017;17(1):479. doi:10.1186/s12906-017-1972-0